A Study to Test the Safety, Tolerability, and Blood Levels of UCB0022 in Healthy Participants and Participants With Parkinson's Disease

Exclusion Criteria

• •Participant has history or presence of cerebro/cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, psychiatric or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data
• •Participant has a high risk for cardiovascular accident based on family history or on laboratory test
• •Participants with hypertension requiring medical treatment within 6 months before the Screening, or with clinically significant orthostatic hypotension
• •Participant has a known hypersensitivity to any components of the study medication or comparative drugs (and/or an investigational device) as stated in this protocol
• •Participant has a history of unexplained syncope or a family history of sudden death due to long QT syndrome
• •Participant has active neoplastic disease or history within the past 5 years of screening visit except for basal cell or squamous epithelial carcinomas of the skin that have been treated with SOC. Study participant has a history of a major organ transplant or hematopoietic stem cell/marrow transplant
• •Participant has past or intended use of over-the-counter or prescription medication including herbal medications within 2 weeks or 5 half-lives prior to dosing
• •Participant has used hepatic enzyme-inducing drugs within 2 months prior to dosing
• •Participant has alanine transaminase (ALT), aspartate aminotransferase (AST), or alkaline phosphatase (ALP) \>1.0x upper limit of normal (ULN)
• •Participant has current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
• •Participant has a current history of alcohol or drug use disorder within the last Y Statistical Manual of Mental Disorders Version 5 (DSM-5), within the last year
• •Participant has any clinically relevant electrocardiogram (ECG) finding at the Screening Visit or at Baseline
• •Participant has the presence of hepatitis B surface antigen (HBsAg) at Screening or within 3 months prior to dosing
• •Participant has a positive hepatitis C antibody test result at Screening or within 3 months prior to starting study intervention
• •Participant has a positive human immunodeficiency virus (HIV) antibody test
• •Participant has clinical signs and symptoms consistent with COVID-19 or had a positive Sars-Cov-2 test result within the last 4 weeks prior to dosing
• •Active treatment or a history of glaucoma
• •Part C only:
• •Participant with implantable intracranial stimulator or history of intracranial surgery
• •Participant with documented diagnosis of dementia or a Montreal Cognitive Assessment (MoCA) score \<26 at screening
• •Participant with history of psychotic symptoms (including significant hallucinations) requiring treatment with an antipsychotic medication within the 12 months prior to Admission